Cost-effectiveness of asenapine in the treatment of bipolar i disorder patients with mixed episodes

Journal of Medical Economics

Volumn 17, Issue 7, 2014, Pages 508-519

  Sawyer, Laura ^a   Azorin, Jean Michel ^b   Chang, Stacey ^a   Rinciog, Claudia ^a   Guiraud Diawara, Alice ^c   Marre, Caroline ^c   Hansen, Karina ^c  

^a Showa University Koto Hospital   (United Kingdom)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c Lundbeck   (France)

Author keywords

Asenapine; Bipolar I disorder; Cost effectiveness; Cost utility; Mixed episodes; Olanzapine; QALY

Indexed keywords

ASENAPINE; LITHIUM; OLANZAPINE; PROCYCLIDINE; QUETIAPINE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR I DISORDER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIXED MANIA AND DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NATIONAL HEALTH SERVICE; POST HOC ANALYSIS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RELAPSE; SIDE EFFECT; WEIGHT GAIN; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; STATISTICAL MODEL; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE; WEIGHT GAIN;

EID: 84903161836     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.914030     Document Type: Article

References (60)

1. Hirschfeld RM, Vornik LA. Bipolar disorder-costs and comorbidity. Am J Manag Care 2005;11:S85-90
2. Muller-Oerlinghausen B, Berghofer A, et al. Bipolar disorder. Lancet 2002;359:241-7 (Pubitemid 34113827)
3. Das GR, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002;180:227-33
4. Fajutrao L, Locklear J, Priaulx J, et al. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health 2009;5:3
5. Kleine-Budde K, Touil E, Moock J, et al. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord 2013; epub ahead of print. Available at: http://onlinelibrary.wiley.com/doi/10.1111/bdi. 12165/abstract [Last accessed 20 December 2013]
6. Kleinman L, Lowin A, Flood E, et al. Costs of bipolar disorder. Pharmacoeconomics 2003;21:601-22 (Pubitemid 36808214)
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th edn. Arlington, VA: American Psychiatric Publishing, 2013
8. Martin-Carrasco M, Gonzalez-Pinto A, Galan JL, et al. Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes. Ann Gen Psychiatry 2012;11:7
9. Rosa AR, Reinares M, Franco C, et al. Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord 2009;11:401-9
10. Michalak EE, Guiraud-Diawara A, Sapin C. Asenapine treatment and healthrelated quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials. Curr Med Res Opin 2014;30:711-18
11. Hirschfeld RM, Vornik LA. Bipolar disorder-costs and comorbidity. Am J Manag Care 2005;11:S85-90
12. Muller-Oerlinghausen B, Berghofer A, et al. Bipolar disorder. Lancet 2002;359:241-7 (Pubitemid 34113827)
13. Das GR, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002;180:227-33
14. Fajutrao L, Locklear J, Priaulx J, et al. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health 2009;5:3
15. Kleine-Budde K, Touil E, Moock J, et al. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord 2013; epub ahead of print. Available at: http://onlinelibrary.wiley.com/doi/10.1111/bdi. 12165/abstract [Last accessed 20 December 2013]
16. Kleinman L, Lowin A, Flood E, et al. Costs of bipolar disorder. Pharmacoeconomics 2003;21:601-22 (Pubitemid 36808214)
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th edn. Arlington, VA: American Psychiatric Publishing, 2013
18. Martin-Carrasco M, Gonzalez-Pinto A, Galan JL, et al. Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes. Ann Gen Psychiatry 2012;11:7
19. Rosa AR, Reinares M, Franco C, et al. Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord 2009;11:401-9
20. Michalak EE, Guiraud-Diawara A, Sapin C. Asenapine treatment and healthrelated quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials. Curr Med Res Opin 2014;30:711-18 Journal of Medical Economics Volume 17, Number 7 July 2014 518 Cost-effectiveness of asenapine in BD-I patients with mixed episodes Sawyer et al. www.informahealthcare.com/jme ! 2014 Informa UK Ltd
21. Gonzalez-Pinto A, Barbeito S, Alonso M, et al. Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain. J Clin Psychiatry 2011;72:671-6
22. Osby U, Tiainen A, Backlund L, et al. Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden. J Affect Disord 2009;115:315-22
23. Kupfer DJ, Frank E, Grochocinski VJ, et al. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatrica 2000;12: 110-14
24. Vieta E, Valenti M. Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord 2013;148:28-36
25. National Collaborating Centre for Mental Health. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number London, UK: The British Psychological Society and Gaskell, 2006
26. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44
27. American Psychiatric Association. Mixed Features Specifier. 2013. http://www.dsm5.org/Documents/Mixed%20Features%20Specifier%20Fact%20 Sheet.pdf. [Last accessed 16 December 2013]
28. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord 2013;145:62-9
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Text Revision (DSM-IV-TR). 5th edn. Arlington, VA: American Psychiatric Publishing, Inc., 2000
30. All Wales Medicines Strategy Group. Aripiprazole (Abilify) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. 2009
31. Chisholm D, van OM, Ayuso-Mateos JL et al. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry 2005;187:559-67 (Pubitemid 41752746)
32. Fajutrao L, Paulsson B, Liu S, et al. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clin Ther 2009;31:1456-68
33. Klok RM, Al Hadithy AF, van Schayk NP, et al. Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder. Expert Rev Pharmacoecon Outcomes Res 2007;7:459-67 (Pubitemid 350120040)
34. Lebmeier M, Dudley E, Pericleous L, et al. The cost effectiveness of aripiprazole in patients with bipolar I disorder in the UK. ISPOR 13th Annual European Congress. ISPOR 13th Annual European Congress. Prague. ISPOR 13th Annual European Congress, 2010
35. McKendrick J, Cerri KH, Lloyd A, et al. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. J Psychopharmacol 2007;21:588-96 (Pubitemid 47472733)
36. Ramirez de Arellano A, Rubio-Terres C, Baca E, et al. Economic evaluation analysis in the treatment of bipolar disorder with aripiprazole and other atypical antipsychotic drugs in Spain. ISPOR 13th Annual European Congress. ISPOR 13th Annual European Congress. Prague. ISPOR 13th Annual European Congress, 2010
37. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence, 2008
38. Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011;129:14-26
39. Azorin JM. Personal Communication. 2013
40. Vieta E, Gunther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-49
41. Ekman M, Lindgren P, Miltenburger C, et al. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. Pharmacoeconomics 2012;30:513-30
42. Soares-Weiser K, Bravo VY, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007;11:iii-206
43. Vieta E, Suppes T, Ekholm B, et al. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord 2012;142:36-44
44. Department of Health. Hospital Episode Statistics, Admitted Patient Care-England 2011-12. 2013. http://www.hscic.gov.uk/searchcatalogue productid=9161&q=title%3a%22Hospital+Episode+Statistics%3a+ Admitted+patient+care%22&sort=Relevance&size=10&page=1#top. [Last accessed 16 December 2013]
45. Office for National Statistics. UK Interim Life tables, England and Wales, 2009-2011. 2013. http://www.ons.gov.uk/ons/taxonomy/index.htmlnscl= Interim+Life+Tables#tab-data-tables. [Last accessed 16 December 2013]
46. Office of National Statistics. Mortality statistics: deaths registered in England and Wales. 2012. http://www.ons.gov.uk/ons/rel/vsob1/mortality- statistics-deaths-registered-in-england-and-wales-series-dr-/2011/index.html. [Last accessed 16 December 2013]
47. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-81 (Pubitemid 34628324)
48. Post-hoc analysis of ARES trial dataset. Data on File. 2013
49. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008;11:1131-43
50. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 2010;13:509-18
51. Joint Formulary Committee. British national formulary (BNF) 66, 66th edn. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain, 2013
52. Curtis L. Unit costs of social health care. Canterbury, UK: Personal Social Services Research Unit, University of Kent, 2012
53. Department of Health. NHS reference costs 2010-2011. 2012. https://www.gov.uk/government/publications/2010-11-reference-costs-publication. [Last accessed 16 December 2013]
54. Department of Health. NHS reference costs 2011-2012. 2013. https://www.gov.uk/government/publications/nhs-reference-costs-financial-year- 2011-to-2012. [Last accessed 16 December 2013]
55. Brunelle J, Consoli A, Tanguy ML, et al. Phenomenology, socio-demographic factors and outcome upon discharge of manic and mixed episodes in hospitalized adolescents: a chart review. Eur Child Adolesc Psychiatry 2009;18:185-93
56. Bridle C, Palmer S, Bagnall AM, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 2004;8:iii-187
57. Lam DH, McCrone P, Wright K, et al. Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study. Br J Psychiatry 2005;186:500-6 (Pubitemid 40834870)
58. Revicki DA, Hanlon J, Martin S, et al. Patient-based utilities for bipolar disorder-related health states. J Affect Disord 2005;87:203-10 (Pubitemid 41039942)
59. Hayhurst H, Palmer S, Abbott R, et al. Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res 2006;15:1271-80 (Pubitemid 44682364)
60. Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105